Bradykinin and Preconditioning Against Infarction

  • Tetsuji Miura
  • Jun Sakamoto
  • Takayuki Miki
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 194)


Bradykinin is a peptide consisting of nine amino acids, which is generated by the plasma kallikrein-kinin system as well as the glandular (tissue) kallikrein-kinin system and plasma aminopeptidase (Fig. 11-1). There are at least two classes of bradykinin receptors, i.e. Bl and B2 receptors, and bradykinin exerts its action on most of the cardiovascular system through B2 receptors. Although bradykinin production in ischemic myocardium was first reported almost 30 years ago, the significance of kinin in myocardial ischemic injury did not receive wide-spread attention for decades. Recently, a specific and potent B2 receptor antagonist Hoe 140 (icatibant) became available, and several important aspects of bradykinin in the pathophysiology of myocardial ischemia have been clarified in the past several years. Firstly, it has been suggested that activation of the B2 receptor before ischemia may protect the heart against ischemia/reperfusion injury, including arrhythmia, contractile dysfunction and necrosis. Secondly, bradykinin may play a role in an endogenous cardioprotective mechanism, ischemic preconditioning (i.e. cardioprotective effect of brief transient non-lethal ischemia). This article briefly reviews the involvement of bradykinin in the enhancement of myocardial tolerance against infarction by ischemic preconditioning.


Adenosine Receptor Ischemic Precondition Myocardial Ischemic Injury Infarct Size Limitation Sustained Ischemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994;270:68l–9.Google Scholar
  2. 2.
    Miki T, Miura T, Ogawa T et al. Captopril, a kininase II inhibitor, lowers the threshold of preconditioning through B2 receptor mediate mechanism. [Abstract] Circulation 1995;92 (suppl.I):1–455.CrossRefGoogle Scholar
  3. 3.
    Downey JM, Miura T. “The role of adenosine in ischemic preconditioning. ” In Cardiac Adaptation and Failure,Hori M, Maruyama Y, Reneman RS, ed. Tokyo: Springer-Verlag, 1994.Google Scholar
  4. 4.
    Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation. Am J Physiol 1993;265:H504–8.PubMedGoogle Scholar
  5. 5.
    Miura T. Adenosine and bradykinin: Are they independent triggers of preconditioning? Basic Res Cardiol 1996;91:20–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakamoto J, Miura T, Goto M et al. Limitation of myocardial infarct size by adenosine Al-receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 1995;29:682–8.PubMedGoogle Scholar
  7. 7.
    Goto_M, Liu Y, Yang X-M et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Parratt JR. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacological exploitation. TiPS 1994;15:15–25.Google Scholar
  9. 9.
    Murry CE, Richard VJ, Reimer KA et al. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990,66:913–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Steenbergen C, Perlman ME, London RE et al. Mechanism of preconditioning. Ionic alterations. Circ Res 1993;72:112–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Linz W, Wiemer G, Scholkens BA. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes 1996;45 (Suppl.l):S51–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhu P, Zaugg CE, Simper D et al. Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide and prostacyclin. Cardiovasc Res 1995;29:658–63.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Tetsuji Miura
  • Jun Sakamoto
  • Takayuki Miki

There are no affiliations available

Personalised recommendations